Wuhan General Group is a Nevada state public incorporation trading on the Over The Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
The Company is currently positioning itself to become a major player in the 146.4 billion dollars growing medical CBD (cannabidiol) space as well as the promising psilocybin medical health sector. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies. has entered CBD by-product market
Wuhan General Group through its wholly-owned subsidiary MJ MedTech, a nutraceutical company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx brand. In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness.
The Company, with its newly acquired stake in Biodelta Nutraceuticals (ISO 22000 and organic certified) a Cape Town-based manufacturer and merchandiser of premium health products to all pharmacy & health shop chains across South Africa, will be launch Dr. AnnaRx products and distribute in 4000 pharmacies in South Africa and adjacent countries. Our next phase is to go international: US, Canada, Australia, and Europe.